These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 12583451)

  • 1. Long-term HIV/AIDS survival estimation in the highly active antiretroviral therapy era.
    King JT; Justice AC; Roberts MS; Chang CC; Fusco JS;
    Med Decis Making; 2003; 23(1):9-20. PubMed ID: 12583451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
    Patel K; Hernán MA; Williams PL; Seeger JD; McIntosh K; Van Dyke RB; Seage GR;
    Clin Infect Dis; 2008 Feb; 46(4):507-15. PubMed ID: 18199042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
    Wong KH; Chan KC; Lee SS
    Clin Infect Dis; 2004 Sep; 39(6):853-60. PubMed ID: 15472819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A decision tree to help determine the best timing and antiretroviral strategy in HIV-infected patients.
    Piroth L; Fournel I; Mahy S; Yazdanpanah Y; Rey D; Rabaud C; Faller JP; Hoen B; Fardeheb M; Quantin C; Chavanet P; Binquet C;
    Epidemiol Infect; 2011 Dec; 139(12):1835-44. PubMed ID: 21232172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L.
    Wood E; Hogg RS; Yip B; Harrigan PR; O'Shaughnessy MV; Montaner JS
    Ann Intern Med; 2003 Nov; 139(10):810-6. PubMed ID: 14623618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
    Lapadula G; Torti C; Maggiolo F; Casari S; Suter F; Minoli L; Pezzoli C; Di Pietro M; Migliorino G; Ouiros-Roldan E; Ladisa N; Sighinolfi L; Costarelli S; Carosi G;
    Antivir Ther; 2007; 12(6):941-7. PubMed ID: 17926648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating the proportion of patients infected with HIV who will die of comorbid diseases.
    Braithwaite RS; Justice AC; Chang CC; Fusco JS; Raffanti SR; Wong JB; Roberts MS
    Am J Med; 2005 Aug; 118(8):890-8. PubMed ID: 16084183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Life expectancy of patients with newly-diagnosed HIV infection in the era of highly active antiretroviral therapy.
    Fang CT; Chang YY; Hsu HM; Twu SJ; Chen KT; Lin CC; Huang LY; Chen MY; Hwang JS; Wang JD; Chuang CY
    QJM; 2007 Feb; 100(2):97-105. PubMed ID: 17277317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy.
    Kohli R; Lo Y; Howard AA; Buono D; Floris-Moore M; Klein RS; Schoenbaum EE
    Clin Infect Dis; 2005 Sep; 41(6):864-72. PubMed ID: 16107987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
    Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
    HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.
    Wang C; Vlahov D; Galai N; Bareta J; Strathdee SA; Nelson KE; Sterling TR
    J Infect Dis; 2004 Sep; 190(6):1046-54. PubMed ID: 15319852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort.
    Gutierrez F; Padilla S; Masiá M; Iribarren JA; Moreno S; Viciana P; Muñoz L; Gómez Sirvent JL; Vidal F; López-Aldeguer J; Blanco JR; Leal M; Rodríguez-Arenas MA; Perez Hoyos S;
    PLoS One; 2006 Dec; 1(1):e89. PubMed ID: 17183720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection.
    Qurishi N; Kreuzberg C; Lüchters G; Effenberger W; Kupfer B; Sauerbruch T; Rockstroh JK; Spengler U
    Lancet; 2003 Nov; 362(9397):1708-13. PubMed ID: 14643119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term clinical benefit after highly active antiretroviral therapy in advanced HIV-1 infection, even in patients without immune reconstitution.
    Arici C; Ripamonti D; Ravasio V; Maggiolo F; Rizzi M; Finazzi MG; Suter F
    Int J STD AIDS; 2001 Sep; 12(9):573-81. PubMed ID: 11516366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Good adherence to HAART and improved survival in a community HIV/AIDS treatment and care programme: the experience of The AIDS Support Organization (TASO), Kampala, Uganda.
    Abaasa AM; Todd J; Ekoru K; Kalyango JN; Levin J; Odeke E; Karamagi CA
    BMC Health Serv Res; 2008 Nov; 8():241. PubMed ID: 19021908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy.
    Smith CJ; Sabin CA; Youle MS; Kinloch-de Loes S; Lampe FC; Madge S; Cropley I; Johnson MA; Phillips AN
    J Infect Dis; 2004 Nov; 190(10):1860-8. PubMed ID: 15499544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study.
    Palella FJ; Baker RK; Moorman AC; Chmiel JS; Wood KC; Brooks JT; Holmberg SD;
    J Acquir Immune Defic Syndr; 2006 Sep; 43(1):27-34. PubMed ID: 16878047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and prognosis of CMV disease in HIV-infected patients before and after introduction of combination antiretroviral therapy.
    Salzberger B; Hartmann P; Hanses F; Uyanik B; Cornely OA; Wöhrmann A; Fätkenheuer G
    Infection; 2005 Oct; 33(5-6):345-9. PubMed ID: 16258865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individual variation in CD4 cell count trajectory among human immunodeficiency virus-infected men and women on long-term highly active antiretroviral therapy: an application using a Bayesian random change-point model.
    Chu H; Gange SJ; Yamashita TE; Hoover DR; Chmiel JS; Margolick JB; Jacobson LP
    Am J Epidemiol; 2005 Oct; 162(8):787-97. PubMed ID: 16135508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low versus high CD4 cell count as starting point for introduction of antiretroviral treatment in resource-poor settings: a scenario-based analysis.
    Bogaards JA; Weverling GJ; Geskus RB; Miedema F; Lange JM; Bossuyt PM; Goudsmit J
    Antivir Ther; 2003 Feb; 8(1):43-50. PubMed ID: 12713063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.